RecruitingEarly Phase 1NCT07336823

JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma

A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of JY232 Injection in Patients With Relapsed/Refractory Multiple Myeloma

Sponsor

Shenzhen Genocury Biotech Co., Ltd.

Enrollment

9 participants

Start Date

Jan 20, 2026

Study Type

INTERVENTIONAL

Conditions

Multiple Myeloma

Summary

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed/refractory multiple myeloma. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY232 injection in the treatment of relapsed/refractory multiple myeloma.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new treatment called JY232 injection in people with multiple myeloma (a blood cancer) that has come back or is no longer responding to treatment. The study is evaluating its safety and how well it works. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with active, relapsed, or treatment-resistant multiple myeloma - You have received at least 2 prior lines of therapy, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 therapy - You have had a stem cell transplant or are not eligible for one **You may NOT be eligible if...** - Your cancer has spread to the brain or spinal cord - You have an uncontrolled infection or serious health condition - Your organ function or blood counts do not meet study requirements - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGJY232 Injection

This open-label, single-arm study is designed to evaluate the efficacy and safety of an in vivo Chimeric Antigen Receptor T-cell (CAR-T) therapy (JY232 preparation) in patients with relapsed or refractory multiple myeloma. Enrolled subjects will receive a single intravenous infusion of JY232, followed by a mandatory one-month in-hospital observation period for initial safety and efficacy assessments. Subsequently, subjects will enter a follow-up phase lasting up to 2 years to monitor long-term disease control.